As of Jan 10, 2025, United Therapeutics Corporation Intrinsic Value is $421.5. This suggests it may be undervalued by 15.5% compared to its current price of around $365.0.
As of Jan 10, 2025, United Therapeutics Corporation's Discounted Cash Flow (DCF) valuation estimates its share price at $428.1. This suggests it may be overvalued by 17.3% to its current price of around $365.0, using a discount rate of 7.8% and terminal growth rate of 3.0%.
United Therapeutics Corporation is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $421.5, compared to a market price of around $365.0. This suggests a potential undervaluation of 15.5%.